世界卫生组织《耐药结核病和丙型病毒性肝炎治疗的联合管理(2024快讯版)》解读OA北大核心CSTPCD
Interpretation of World Health Organization's Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C:2024 Update
世界卫生组织于2024年4月9日发布了《耐药结核病和丙型肝炎治疗的联合管理(2024 快讯版)》.本文中,笔者介绍了该指南内容的要点,包括耐药结核病与丙型病毒性肝炎共病治疗管理的背景、指南更新的主要关键证据及主要发现,并总结下一步指南更新方向,同时,就该指南在中国临床实践的可行性和未来研究方向提出了思考和讨论.
On April 9,2024,the World Health Organization published the updated guidelines for the Co-administration of Treatments for Drug-resistant Tuberculosis and Hepatitis C,as part of a rapid communication effort.This paper elucidates key aspects of the guideline,detailing the epidemiological background,pivotal evidence underpinning the updates,and significant findings.A comprehensive summary and forthcoming steps for the guideline's advancement are presented.Additionally,the authors evaluate the practical applicability of these guidelines in Chinese clinical settings and propose areas for future research,aiming to enhance the management of these coexisting conditions.
杨梁梓;张培泽;卢水华
深圳市第三人民医院/南方科技大学第二附属医院/国家感染性疾病临床医学研究中心,深圳 518112
临床医学
结核,肺抗药性,细菌肝炎,丙型共病现象疾病管理
Tuberculosis,pulmonaryDrug resistance,bacterialHepatitis CComorbidityDisease management
《中国防痨杂志》 2024 (008)
874-876 / 3
Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties(SZGSP010);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Guangdong Clinical Research Center for Tuberculosis(2020B1111170014)广东省高水平临床重点专科基金深圳市配套经费资助(结核病科,SZGSP010);深圳市结核病临床研究中心(20210617141509001);广东省感染性疾病(结核病)临床医学研究中心(2020B1111170014)
评论